What changed: the shortage resolved
The FDA marked the semaglutide shortage 'resolved' in February 2025, ending the window where pharmacies could routinely compound copies of GLP-1 drugs. That single change reshaped what you can legally say and sell — and a lot of med spa ads and websites are now out of date and exposed.
What's still legal in 2026
Plenty. Branded GLP-1 prescribing, narrow 503B outsourcing-facility supply, and patient-specific 503A compounding when there's documented clinical need all remain viable. Medical weight-loss is absolutely still a business — you just have to message it correctly.
LegitScript is now non-negotiable
Google requires LegitScript certification before it will run most weight-loss and prescription-adjacent ads. As of 2026, Visa and Mastercard also require it for GLP-1 merchants — without it, most acquiring banks decline you. If you're running GLP-1 ads without certification, you're one review away from a shutdown.
The claims that get you flagged
Don't call compounded GLP-1s 'generic,' 'equivalent,' or claim identical outcomes to the branded drug — that's exactly what the FDA and the National Advertising Division (backed by Eli Lilly and Novo Nordisk) are targeting. And per FTC rules, testimonials must reflect typical results — never feature only your best outlier.
How to stay compliant AND booked
Get LegitScript certified, keep your ad and website claims current with FDA positioning, sell the supervised program and the experience rather than 'cheap semaglutide,' and document everything. Done right, compliance is a competitive moat — most of your local competitors don't track any of this, and their accounts are the ones getting flagged.